Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...

The gross proceeds to the Company from the registered direct offering are estimated to be approximately $1.0 million, before deducting the placement agent’s fees and other estimated offering expenses.

In 1978, the Corporation Commission found that he had committed securities fraud for making false or misleading statements ...

Orchestrating intelligent agent flows: The Dayforce platform smoothly coordinates ... Annual Reports on Form 10-K and other reports we file with the Securities and Exchange Commission. Copies of ...

Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

The Infosys CMO Radar 2024 found that marketing leaders expect AI to deliver measurable value in the next 18 months, including double-digit percentage point boosts in productivity (15 percentage ...

Additionally, Cameco filed a short form base shelf prospectus dated November 12, 2024 (the "Base Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories ...

A Form 25 will be filed with the Securities and Exchange Commission to effect the withdrawal of the listing ... Shares will be made by Equiniti Trust Company, LLC, as paying agent (the "Paying Agent") ...

Roth Capital Partners and Northland Capital Markets acted as the co-placement agents for the offering ... originally filed ...

Top Stories of The WeekBTC investors pour $1.1B into BlackRock ETF as Bitcoin marks another highThe worlds largest asset ...

Aduro Clean Technologies Inc. (“ Aduro ” or the “ Company ”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5 ), a clean technology ...